Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Carboplatinum|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: AZ-VUB
Collaborators: Universitaire Ziekenhuizen KU Leuven|Universitair Ziekenhuis Brussel